Researchers at the Lewis Katz School of Medicine at Temple University hope to gain new insight into the relationship between HIV and heart disease, as well as the effect of substance use on this relationship, thanks to the support of a National Institute on Drug Abuse Avenir Award, part of the National Institutes of Health (NIH) Director’s New Innovator (DP2) Award Program. The DP2 award – a first for Temple – is highly competitive, supporting transformative research in high-priority areas designated by the NIH. The funding, $2,377,500, spread over four years, will support studies led by Allison M. Andrews, PhD, Assistant Professor in the Department of Pathology and Laboratory Medicine at the Katz School of Medicine. Scienmag and News-Medical.net highlighted the award.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH